3 years ago

Ledipasvir and Tenofovir drug interaction in HIV-HCV co-infected patients: Impact on Tenofovir Ctrough and Renal Safety

Olivia Faucher-Zaegel, Bruno Lacarelle, Sylvie Bregigeon, Isabelle Poizot-Martin, Sylvie Quaranta, Véronique Obry-Roguet, Caroline Solas, Catherine Tamalet
We evaluate the impact of ledipasvir on both tenofovir plasma trough concentration (Ctrough) and estimated glomerular renal function (eGFR) in HIV-HCV co-infected patients receiving a tenofovir(TDF)-based antiretroviral regimen and treated with ledipasvir/sofosbuvir. Twenty-six patients [81% male, median age: 51years; HCV genotype 1(75%)/4(15%)] were included. Tenofovir Ctrough (interquartile:IQR) increased from 78ng/mL (53-110) at baseline to 141ng/mL (72-176) at M1 (p=0.003). No significant difference on eGFR using both Cockroft-Gault and MDRD formula, respectively [median(IQR)] was observed between baseline [101.3ml/min (91.1-114.1); 95.6ml/min (86.5-111.2)], M1 [102.4ml/min (89.8-112.9), p=0.26; 92.5ml/min (88.1-114.3), p=0.27], end-of-treatment [96.5ml/min (82.4-115.4), p=0.39; 95.4ml/min (84.2-105.4), p=0.16] and 12-weeks after the end of treatment [100.5ml/min (83.3-111.9), p=0.24; 93.4ml/min (82.2-103.5), p=0.16]. Three patients progressed from CKD stage 1 to stage 2 at PT12. A significant increase in tenofovir exposure through P-gp inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bcp.13450

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.